OriGene Announces the Release of Specificity-Verified UltraMAB™ Antibodies
Product News Sep 24, 2012
OriGene Technologies has announced the release of a new line of ultra specific and extensively validated monoclonal antibodies under the UltraMAB™ brand.
UltraMAB Antibodies are a collection of monoclonal antibodies which are exclusively developed by OriGene for IHC applications and are the industry's only antibody products available on the market that have been validated with the Company's breakthrough 10K High Density Protein Microarray Technology.
OriGene's 10K High Density Protein Microarray Platform enables the screening of candidate antibodies against greater than 10,000 human proteins to identify the most specific monoclonal antibodies for IHC applications.
"High-specificity is the pre-requisite for any IHC antibody because IHC detection relies on only one antibody against a complex tissue sample. Through the use of novel and proprietary technologies such as our 10K High-Density Protein Microarray Platform, OriGene has dramatically improved the specificity of antibodies available to the global market place. By validating all UltraMAB antibodies against our 10K High-Density Protein Microarray Platform, the market now has access to one of the industry's most significant tools for IHC detection and determination of accurate results," said Dr. Wei-Wu He, Ph.D., CEO & Chairman, OriGene Technologies.
Each UltraMAB™ is validated for IHC and for immunoassay analysis, and determined to have no cross-reactivity with other human proteins other than the antibody's intended target protein as determined by OriGene's 10K High Density Protein Microarray Platform.
Consequently, each UltraMAB™ is quality control verified, guaranteeing superior performance for IHC applications, where specificity-verification and the highest quality antibodies are critical for accurate detection.
Detailed information about the UltraMAB™ Antibodies is available at www.origene.com/UltraMAB, where customers can learn more about OriGene's unique approach to monoclonal antibody development and contact the company's representatives to explore collaborative opportunities.